STOCK TITAN

Xenetic Biosciences Inc - XBIO STOCK NEWS

Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.

Xenetic Biosciences Inc (NASDAQ: XBIO) is a clinical-stage biopharmaceutical leader advancing novel immuno-oncology therapies through its DNase platform and polyxen™ technology. This page provides investors and researchers with centralized access to the company’s latest developments in cancer treatment innovation.

Find timely updates on XBIO’s clinical trial progress, strategic collaborations, and regulatory milestones. Our curated collection includes press releases about orphan-designated therapies, CAR T platform advancements, and preclinical research insights – all essential for tracking the company’s contributions to targeted cancer treatments.

Key updates cover three focus areas: clinical developments in hard-to-treat cancers, technology partnerships enhancing therapeutic efficacy, and scientific publications validating novel approaches to tumor microenvironment modulation. Bookmark this page to stay informed about Xenetic’s progress in developing next-generation biologics and combination therapies.

Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) has announced a significant collaboration with The Scripps Research Institute to advance its systemic DNase-based oncology program, aimed at treating pancreatic carcinoma and other solid tumors. This partnership will enhance the development of the DNase platform, which targets neutrophil extracellular traps (NETs), implicated in cancer progression and therapeutic resistance. Xenetic plans to initiate a first-in-human study assessing the DNase in combination with immune checkpoint inhibitors or chemotherapy. Furthermore, the agreement allows Xenetic to acquire an exclusive license for any new intellectual property resulting from the research. This collaboration is seen as a critical step towards creating much-needed therapies for challenging cancer indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
none
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) reported significant developments in its annual results for 2022. The company is focusing on the DNase oncology platform, which targets neutrophil extracellular traps to improve cancer therapies. The DNase program is progressing towards Phase 1 clinical development and aims to provide treatments for pancreatic carcinoma and other solid tumors. The year ended with approximately $13.1 million in cash. Financially, the net loss for 2022 was $6.6 million, with a 50.8% increase in research and development expenses. A royalty payment of $1.7 million was received from a sublicense with Takeda, marking a 47.1% year-over-year increase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced participation in the Virtual Investor NETs in Cancer Spotlight Event on March 29, 2023, at 11:00 AM ET. CEO Jeffrey Eisenberg, CSO Curtis Lockshin, and oncology leader Dr. Jonathan Spicer will discuss the Company's DNase-based oncology platform and the role of Neutrophil Extracellular Traps (NETs) in cancer. The event will feature a moderated roundtable discussion, enabling investors to submit questions live. A live video webcast will be available on Xenetic's website and archived for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.97%
Tags
conferences
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) announced that the Canadian Intellectual Property Office has issued a notice of allowance for Patent Application No. 3,001,543, titled Method to Improve Safety and Efficacy of Anti-Cancer Therapy. This patent application aims to improve treatments for cancer patients by using a DNase enzyme to mitigate chemotherapy-associated side effects. CEO Jeffrey Eisenberg emphasized the company's commitment to advancing its DNase platform and strengthening its intellectual property portfolio. The approved patent enhances Xenetic's capabilities in the oncology sector, specifically targeting pancreatic carcinoma and other difficult-to-treat cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.89%
Tags
none
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) will present at the Virtual Investor 2023 Companies to Watch Event on January 17, 2023, at 10:00 AM ET. CEO Jeffrey Eisenberg will showcase the company's advancements in immune-oncology technologies aimed at treating hard-to-treat cancers. A live video webcast will be available on the company's Investors website page, with a replay accessible for 90 days post-event. Xenetic specializes in DNase platforms for cancer treatment and the XCART™ technology for personalized CAR T therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.12%
Tags
conferences
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ:XBIO) announced the appointment of Dr. Jonathan Spicer to its Scientific Advisory Board, enhancing its expertise in the role of neutrophil extracellular traps (NETs) in cancer biology. Dr. Spicer, an expert in neoadjuvant immunotherapy for lung cancer, will support the advancement of the Company's DNase platform, which aims to improve cancer treatment outcomes by targeting NETs. This collaboration is pivotal as Xenetic progresses towards a planned Phase 1 study, indicating potential growth in its innovative oncology technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
none
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) reported its financial results for Q3 2022, highlighting progress in its DNase-based oncology platform targeting hard-to-treat cancers. The company ended the quarter with $13.8 million in cash. Notably, net loss was approximately $0.8 million, with R&D expenses down 48.9% to $0.4 million. The company also received $0.4 million in royalties, reflecting an 18.6% increase year-over-year. Xenetic remains focused on advancing its DNase program and collaborations aimed at enhancing cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.36%
Tags
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) announced the signing of a patent assignment from CLS Therapeutics as part of a collaboration with CLS and VolitionRx (NYSE AMERICAN: VNRX) to develop NETs-targeted adoptive cell therapies for cancer. In exchange for the patent, Xenetic will issue 850,000 shares to CLS. This collaboration aims to combine Volition's Nu.Q technology and Xenetic's DNase-Armored CAR T platform, targeting various solid tumors where current therapies are ineffective. The partnership will also share proceeds from any resulting commercial products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) announced the appointment of Allan Tsung, MD to its Scientific Advisory Board. Dr. Tsung, a leading expert in cancers of the liver, bile duct, and pancreas, brings extensive clinical and research experience, aiming to guide the company’s DNase-based oncology platform. His leadership at the University of Virginia and participation in numerous academic surgical organizations positions him to contribute significantly to Xenetic’s development strategies. This appointment is part of the company’s commitment to advancing innovative immune-oncology technologies to address unmet medical needs in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
management
Rhea-AI Summary

Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY, from September 12-14, 2022. Jeffrey F. Eisenberg, the CEO, will present at the event, which will also feature virtual one-on-one meetings for registered investors. A video webcast of the presentation will be available on-demand starting September 12 at 7:00 AM ET, archived for 90 days. The Company is advancing innovative immune-oncology technologies, particularly for hard-to-treat cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
conferences
Xenetic Biosciences Inc

Nasdaq:XBIO

XBIO Rankings

XBIO Stock Data

3.75M
1.25M
19.06%
6.44%
0.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
FRAMINGHAM